Biomarkers and personalized medicine
4 European H2020 organizations list this as part of their work — 4 as their primary capability.
Most active in this area
- UNIVERSITE DE GENEVE
Swiss research university leading in neuroscience, brain imaging, biomarkers, and AI-driven personalized medicine across 200+ EU projects.
“Recurring keywords across both periods — biomarkers, personalized medicine, diabetes, cardiovascular — spanning projects like CoSTREAM and health-sector RIAs”
PrimaryCH203 projects - FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Barcelona-based biomedical research institute specializing in liver disease, HIV immunotherapy, brain research, and personalized medicine through clinical trials and multi-omics.
“Recurring theme across projects including CATCH ME (atrial fibrillation biomarkers), T2DSystems (diabetes omics), MultipleMS (MS biomarkers), and HarmonicSS (Sjögren's syndrome analytics).”
PrimaryES88 projects - HOSPITAL CLINIC DE BARCELONA
Major Barcelona teaching hospital providing clinical expertise, patient cohorts, and trial sites across liver disease, HIV, neuroscience, and chronic care research.
“Recurrent theme across T2DSystems, R-LiNK, CATCH ME, and MEDIT-AGEING — contributing clinical data for biomarker discovery, disease stratification, and treatment personalization.”
PrimaryES64 projects - ASTELLAS PHARMA EUROPE BV
Major Japanese pharma company's European arm, active in IMI partnerships for drug discovery, advanced therapies, and biomarker-driven personalized medicine.
“BEAt-DKD focused on prognostic/predictive biomarkers for diabetic kidney disease; PIONEER on genetic profiling for prostate cancer; BEAMER on patient adherence models.”
PrimaryNL9 projects